Gastric Cancer News and Research

RSS

Weight, socioeconomic status may affect risk of developing esophageal and gastric cancer

Overweight adolescents were twice as likely as their normal weight peers to later develop esophageal cancer in a recent study from Israel. The study, which is published early online in CANCER, a peer-reviewed journal of the American Cancer Society, also found that lower socioeconomic status as well as immigration from higher risk countries were important determinants of gastric cancer.

14 Oct 2013

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Surgeons at UC San Diego Health System have performed the region's first robotic gastrectomy, a potentially lifesaving procedure to remove a section of the stomach after a diagnosis of gastric cancer. Aided by a da Vinci robot, surgeons remove the diseased tissue, perform a delicate reconstruction and remove local lymph nodes for further testing.

3 Oct 2013

Researchers identify potentially treatable subtype of pancreatic cancer

Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.

17 Sep 2013

Global Industry Analysis Report on Companion Diagnostics Market

New Market Research Report Added in MarketResearchReports.Biz Reports Database Companion Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

12 Sep 2013

ASTRO selects Jean B. Owen as 2013 Honorary Member

The American Society for Radiation Oncology has selected health care researcher Jean B. Owen, PhD, as the 2013 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology and radiation physics.

12 Sep 2013

Study shows how stomach bacteria manipulates human immune system to survive in stomach

Helicobacter pylori is a bacterium that establishes a life-long stomach infection in humans, which in some cases can lead to duodenal ulcers or stomach cancer. New research, presented at this week's Society for General Microbiology Autumn Conference, gives us a clearer understanding of how these bacteria can manipulate the human immune system to survive in the mucosal lining of the stomach.

4 Sep 2013

Study shows genetic test to classify gastric cancers and match them to therapies offer best outcomes

Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to researchers at Duke-NUS Graduate Medical School Singapore.

28 Aug 2013

AGA acknowledges partnership of GCF to support research in gastric, esophageal cancer

The American Gastroenterological Association (AGA) Research Foundation is pleased to announce that it has partnered with the Gastric Cancer Foundation (GCF) to create a new grant to support research in gastric and esophageal cancer.

27 Aug 2013

UCLA receives $5M from NIH to develop tool for detecting stomach cancer

Imagine having a sample of your saliva taken at the dentist's office, and then learning within minutes whether your risk for stomach cancer is higher than normal. That futuristic-sounding scenario may actually not be too far from reality.

16 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Exalenz Bioscience launches BreathID Hp to test and treat H. pylori

Exalenz Bioscience, developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and liver conditions, announced today the global launch of the BreathID Hp, a next generation device in the company's BreathID product line.

15 Jul 2013

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

4 Jul 2013

MPIIB researchers show that Chlamydia infections can cause mutations in host DNA

Chlamydia trachomatis is a human pathogen that is the leading cause of bacterial sexually transmitted disease worldwide with more than 90 million new cases of genital infections occurring each year. About 70 percent of women infected with Chlamydia remain asymptomatic and these bacteria can establish chronic infections for months, or even years. Even when it causes no symptoms, Chlamydia can damage a woman's reproductive organs. In addition, standard antibacterial drugs are proving increasingly ineffective in complete eradication, as Chlamydia goes in to persistent mode, leading to asymptomatic chronic infection.

21 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Study reveals a new way for detecting colorectal cancers

A unique new study led by University of Kentucky Markey Cancer Center researchers Guo-Min Li and Libya Gu, in collaboration with Dr. Wei Yang at National Institutes of Health, reveals a novel mechanism explaining the previously unknown root cause of some forms of colorectal cancers.

26 Apr 2013

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax Corp. today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® (ecallantide) business, the broader angioedema portfolio and the Licensing and Funded Research Program (LFRP).